Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

3 weeks ago
R&D
Pharma

Vac­cine biotechs say they’ve been told to stop next-gen Covid work un­der a Biden-era project

3 weeks ago
Pharma
Coronavirus

As­traZeneca re­joins PhRMA, two years af­ter leav­ing lob­by group

3 weeks ago
Pharma

Re­cent FDA staff cuts to de­lay drug hear­ing de­ci­sion by months, agency tells Van­da

3 weeks ago
FDA+
Law

Re­gen­eron to boost its US man­u­fac­tur­ing through a $3B Fu­ji­film deal

3 weeks ago
Pharma
Manufacturing

Gala­pa­gos CEO Paul Stof­fels to step down, for­mer Neumo­ra chief to lead spin­out

3 weeks ago
People

In­sur­ers have a Medicare Ad­van­tage prob­lem

3 weeks ago
Health Tech

Dana­her ex­pects about $350M in tar­iff costs; Alu­mis, Ace­lyrin ad­just deal terms

3 weeks ago
News Briefing

Ex­clu­sive: George Church start­up will study long-lived an­i­mals, hu­mans to find life-ex­tend­ing genes

3 weeks ago
Financing
Startups

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

3 weeks ago
China
Pharma

Pre­ven­tive health start­up Su­per­pow­er rais­es $30M

3 weeks ago
Financing
Health Tech

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

3 weeks ago
Bioregnum

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

3 weeks ago
Pharma
Manufacturing

As­traZeneca, Dai­ichi eye first-line breast can­cer mar­ket af­ter En­her­tu's ear­ly Phase 3 win

3 weeks ago
R&D
Pharma

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

3 weeks ago
FDA+

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

3 weeks ago
FDA+

Alvo­gen unit ap­peals court loss shield­ing Bausch Health's IBS drug from gener­ics

3 weeks ago
Pharma
FDA+

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

3 weeks ago
Startups
R&D

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

3 weeks ago
R&D

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

3 weeks ago
People
R&D

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

3 weeks ago
FDA+

Trump’s ex­ec­u­tive or­der on drug pric­ing; Pfiz­er drops oral obe­si­ty drug; Seed rounds at their low­est in years; and ...

3 weeks ago
Weekly

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

4 weeks ago
Startups
Deals

GSK kicks off Blenrep re­launch plans with clear­ance from UK reg­u­la­tors

4 weeks ago
Pharma
FDA+
First page Previous page 6789101112 Next page Last page
A service from the Financial Times